Jeffrey R. Marks
Jeffrey R. Marks
Verified email at
Cited by
Cited by
Comprehensive molecular portraits of human breast tumours
D Koboldt, R Fulton, M McLellan, H Schmidt, J Kalicki-Veizer, ...
Nature 490 (7418), 61-70, 2012
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild, G Yao, JT Chang, Q Wang, A Potti, D Chasse, MB Joshi, ...
Nature 439 (7074), 353-357, 2006
Predicting the clinical status of human breast cancer by using gene expression profiles
M West, C Blanchette, H Dressman, E Huang, S Ishida, R Spang, H Zuzan, ...
Proceedings of the National Academy of Sciences 98 (20), 11462-11467, 2001
BRCA1 mutations in primary breast and ovarian carcinomas
PA Futreal, Q Liu, D Shattuck-Eidens, C Cochran, K Harshman, ...
Science 266 (5182), 120-122, 1994
The immune landscape of cancer
V Thorsson, DL Gibbs, SD Brown, D Wolf, DS Bortone, THO Yang, ...
Immunity 48 (4), 812-830. e14, 2018
Comprehensive molecular portraits of invasive lobular breast cancer
G Ciriello, ML Gatza, AH Beck, MD Wilkerson, SK Rhie, A Pastore, ...
Cell 163 (2), 506-519, 2015
Comprehensive characterization of cancer driver genes and mutations
MH Bailey, C Tokheim, E Porta-Pardo, S Sengupta, D Bertrand, ...
Cell 173 (2), 371-385. e18, 2018
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics
J Liu, T Lichtenberg, KA Hoadley, LM Poisson, AJ Lazar, AD Cherniack, ...
Cell 173 (2), 400-416. e11, 2018
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
KA Hoadley, C Yau, T Hinoue, DM Wolf, AJ Lazar, E Drill, R Shen, ...
Cell 173 (2), 291-304. e6, 2018
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ...
Journal of clinical oncology 26 (20), 3324-3330, 2008
Genomic signatures to guide the use of chemotherapeutics
A Potti, HK Dressman, A Bild, RF Riedel, G Chan, R Sayer, J Cragun, ...
Nature medicine 12 (11), 1294-1300, 2006
Overexpression and mutation of p53 in epithelial ovarian cancer
JR Marks, AM Davidoff, BJ Kerns, PA Humphrey, JC Pence, RK Dodge, ...
Cancer research 51 (11), 2979-2984, 1991
Compromised HOXA5 function can limit p53 expression in human breast tumours
V Raman, SA Martensen, D Reisman, E Evron, WF Odenwald, E Jaffee, ...
Nature 405 (6789), 974-978, 2000
High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer
AT Ferguson, E Evron, CB Umbricht, TK Pandita, TA Chan, H Hermeking, ...
Proceedings of the National Academy of Sciences 97 (11), 6049-6054, 2000
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
T Baba, PA Convery, N Matsumura, RS Whitaker, E Kondoh, T Perry, ...
Oncogene 28 (2), 209-218, 2009
Artificial neural networks improve the accuracy of cancer survival prediction
HB Burke, PH Goodman, DB Rosen, DE Henson, JN Weinstein, ...
Cancer 79 (4), 857-862, 1997
Machine learning identifies stemness features associated with oncogenic dedifferentiation
TM Malta, A Sokolov, AJ Gentles, T Burzykowski, L Poisson, JN Weinstein, ...
Cell 173 (2), 338-354. e15, 2018
BRCA2 mutations in primary breast and ovarian cancers
JM Lancaster, R Wooster, J Mangion, CM Phelan, C Cochran, C Gumbs, ...
Nature genetics 13 (2), 238-240, 1996
Genetic basis for p53 overexpression in human breast cancer
AM Davidoff, PA Humphrey, JD Iglehart, JR Marks
Proceedings of the National Academy of Sciences 88 (11), 5006-5010, 1991
The system can't perform the operation now. Try again later.
Articles 1–20